Boston Scientific Corp (BSX)vsMasimo Corporation (MASI)
BSX
Boston Scientific Corp
$48.55
-0.32%
HEALTHCARE · Cap: $70.87B
MASI
Masimo Corporation
$178.82
-0.04%
HEALTHCARE · Cap: $9.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1223% more annual revenue ($20.61B vs $1.56B). BSX leads profitability with a 17.3% profit margin vs 4.9%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
MASI
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
+4.8%
Fair Value
$141.85
Current Price
$178.82
$36.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Earnings expanding 214.4% YoY
Safe zone — low bankruptcy risk
Strong operational efficiency at 23.6%
Areas to Watch
No major concerns identified
Trading at 11.9x book value
4.9% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : MASI
The strongest argument for MASI centers on EPS Growth, Altman Z-Score, Operating Margin.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : MASI
The primary concerns for MASI are Price/Book, Profit Margin, PEG Ratio. A P/E of 44.4x leaves little room for execution misses. Thin 4.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a mature stock while MASI is a value play — different risk/reward profiles.
MASI carries more volatility with a beta of 1.10 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 56/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Masimo Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Masimo Corporation develops, manufactures and markets non-invasive monitoring technologies and hospital automation solutions globally. The company is headquartered in Irvine, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?